Reported Saturday, Black Diamond Therapeutics Showcased BDTX-1535 Clinical Data In Patients With Recurrent Glioblastoma At 2024 ASCO Annual Meeting
Reported Saturday, Black Diamond Therapeutics Showcased BDTX-1535 Clinical Data In Patients With Recurrent Glioblastoma At 2024 ASCO Annual Meeting
週六報道，黑鑽療法在 2024 年 ASCO 年會上展示了複發性膠質母細胞瘤患者的 BDTX-1535 臨床數據
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment
BDTX-1535在GBM患者的一期劑量遞增試驗結果表明，具有良好的安全性和耐受性，以及令人鼓舞的抗腫瘤活性和治療持續時間。
Initial data from Phase 0/1 "trigger" ("window of opportunity") investigator-sponsored trial demonstrated BDTX-1535 achieved clinically meaningful drug levels in brain tumor tissue
來自0/1期“觸發器”（“機會窗口”）研究的初步數據表明，BDTX-1535在腦腫瘤組織中實現了具有臨床意義的藥物水平。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。